Journal of Clinical and Cellular Immunology
Open Access
ISSN: 2155-9899
ISSN: 2155-9899
Elizabeth S. Gabitzsch and Frank R. Jones
Recombinant viral vectors have been utilized in the settings of gene therapy, vaccination and immunotherapy but have encountered clinical challenges because they are recognized as foreign entities to the host. This recognition leads to an immunologic clearance of the vector and the inserted gene of interest. We have reported on a new viral vector technology that can be utilized as an immunization modality to induce immune responses even in the presence of vector immunity. We have reported immunization and immunotherapy results to infectious diseases and cancers. This improved viral platform, Ad5 [E1-, E2b-], can be utilized in the development of multiple vaccines and immunotherapies.